Role of mitochondrial dysfunction in Parkinson's disease: Implications for treatment

Drugs and Aging

Volumn 24, Issue 2, 2007, Pages 95-105

  Ramsey, Chenere P ^a   Giasson, Benoit I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; AMINE OXIDASE (FLAVIN CONTAINING); LEUCINE RICH REPEAT KINASE 2; LEVODOPA; NEUROTOXIN;

CELL DAMAGE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC ANALYSIS; HEREDITY; HUMAN; NONHUMAN; PARKINSON DISEASE; POINT MUTATION; PRIORITY JOURNAL; REVIEW;

ALPHA-SYNUCLEIN; HUMANS; MITOCHONDRIA; MUTATION; NEUROTOXINS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 33847298685     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724020-00002     Document Type: Review

References (134)

1. Simuni T, Hurtig HI. Parkinson's disease: the clinical picture. In: Clark CM, Trojanoswki JQ, editors. Neurodegenerative dementias. New York: McGraw-Hill, 2000: 193-203
2. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996 Mar; 55 (3): 259-72
3. Damier P, Hirsch EC, Agid Y, et al. The substantia nigra of the human brain: II -patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999 Aug; 122 (Pt 8): 1437-48
4. Pakkenberg B, Moller A, Gundersen HJ, et al. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 1991 Jan; 54 (1): 30-3
5. Mayeau R, Stern Y, Cote L, et al. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 1984 May; 34 (5): 642-6
6. Forman MS, Lee VM, Trojanowski JQ. Nosology of Parkinson's disease: looking for the way out of a quackmire. Neuron 2005 Aug 18; 47 (4): 479-82
7. Moore DJ, West AB, Dawson VL, et al. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005; 28: 57-87
8. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003 Mar; 24 (2): 197-211
9. Norris EH, Giasson BI, Lee VM. Alpha-synuclein: normal function and role in neurodegenerative diseases. Curr Top Dev Biol 2004; 60: 17-54
10. George JM. The synucleins. Genome Biol 2002; 3 (1): REVIEWS3002
11. Duda JE, Lee VMY, Trojanowski JQ. Neuropathology of synuclein aggregates. J Neurosci Res 2000 Jul 15; 61 (2): 121-7
12. George JM, Jin H, Woods WS, et al. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 1995 Aug; 15 (2): 361-72
13. Iwai A, Masliah E, Yoshimoto M, et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995 Feb; 14 (2): 467-75
14. Withers GS, George JM, Banker GA, et al. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res Dev Brain Res 1997 Mar 17; 99 (1): 87-94
15. Abeliovich A, Schmitz Y, Farinas I, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000 Jan; 25 (1): 239-52
16. Chandra S, Fornai F, Kwon HB, et al. Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci U S A 2004 Oct 12; 101 (41): 14966-71
17. Chandra S, Gallardo G, Fernández-Chacón R, et al. Alpha-synuclein cooperates with CSP alpha in preventing neurodegeneration. Cell 2005 Nov 4; 123 (3): 383-96
18. Fernandez-Chacon R, Wolfel M, Nishimune H, et al. The synaptic vesicle protein CSP alpha prevents presynaptic degeneration. Neuron 2004 Apr 22; 42 (2): 237-51
19. Ungar D, Hughson FM. SNARE protein structure and function. Annu Rev Cell Dev Biol 2003; 19: 493-517
20. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997 Jun 27; 276 (5321): 2045-7
21. Markopoulou K, Wszolek ZK, Pfeiffer RF, et al. Reduced expression of the G209A alpha-synuclein allele in familial Parkinsonism. Ann Neurol 1999 Sep; 46 (3): 374-81
22. Athanassiadou A, Voutsinas G, Psiouri L, et al. Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein. Am J Hum Genet 1999 Aug; 65 (2): 555-8
23. Papadimitriou A, Veletza V, Hadjigeorgiou GM, et al. Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance? Neurology 1999 Feb; 52 (3): 651-4
24. Spira PJ, Sharpe DM, Halliday G, et al. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann Neurol 2001 Mar; 49 (3): 313-9
25. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998 Feb; 18 (2): 106-8
26. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004 Feb; 55 (2): 164-73
27. Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003 Oct 31; 302 (5646): 841
28. Farrer M, Kachergus J, Forno L, et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004 Feb; 55 (2): 174-9
29. Chartier-Harlin MC, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004 Sep 25; 364 (9440): 1167-9
30. Spillantini MG, Schmidt ML, Lee VMY, et al. Alpha-synuclein in Lewy bodies. Nature 1997 Aug 28; 388 (6645): 839-40
31. Spillantini MG, Crowther RA, Jakes R, et al. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 1998 May 26; 95 (11): 6469-73
32. Spillantini MG, Crowther RA, Jakes R, et al. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 1998 Jul 31; 251 (3): 205-8
33. Tu PH, Galvin JE, Baba M, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 1998 Sep; 44 (3): 415-22
34. Takeda A, Mallory M, Sundsmo M, et al. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol 1998 Feb; 152 (2): 367-72
35. Irizarry MC, Growdon W, Gomez-Isla T, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol 1998 Apr; 57 (4): 334-7
36. Giasson BI, Uryu K, Trojanowski JQ, et al. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 1999 Mar 19; 274 (12): 7619-22
37. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998 Nov; 4 (11): 1318-20
38. Hashimoto M, Hsu LJ, Sisk A, et al. Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res 1998 Jul 20; 799 (2): 301-6
39. Narhi L, Wood SJ, Steavenson S, et al. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem 1999 Apr 2; 274 (14): 9843-6
40. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001; 2: 492-501
41. Greenbaum EA, Graves CL, Mishizen-Eberz AJ, et al. The E46K mutation in alpha-synuclein increases amyloid fibril formation. J Biol Chem 2005 Mar 4; 280 (9): 7800-7
42. Giasson BI, Duda JE, Quinn SM, et al. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 2002 May 16; 34 (4): 521-33
43. Lee MK, Stirling W, Xu Y, et al. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A 2002 Jun 25; 99 (13): 8968-73
44. Goldberg MS, Lansbury PT. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol 2000 Jul; 2 (7): E115-9
45. Langston JW, Ballard P, Tetrud JW, et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983 Feb 25; 219 (4587): 979-80
46. Javitch JA, D'Amato RJ, Strittmatter SM, et al. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci U S A 1985 Apr; 82 (7): 2173-7
47. Przedborski S, Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov Disord 1998; 13 Suppl. 1: 35-8
48. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 1985; 36 (26): 2503-8
49. Langston JW, Forno LS, Tetrud J, et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine exposure. Ann Neurol 1999 Oct; 46 (4): 598-605
50. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985 Jul; 35 (7): 949-56
51. Shimoji M, Zhang L, Mandir AS, et al. Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease. Brain Res Mol Brain Res 2005 Mar 24; 134 (1): 103-8
52. Fornai F, Schluter OM, Lenzi P, et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci U S A 2005 Mar 1; 102 (9): 3413-8
53. Drolet RE, Behrouz B, Lookingland KJ, et al. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology 2004 Sep; 25 (5): 761-9
54. Schluter OM, Fornai F, Alessandri MG, et al. Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuroscience 2003; 118 (4): 985-1002
55. Dauer W, Kholodilov N, Vila M, et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A 2002 Oct 29; 99 (22): 14524-9
56. Betarbet R, Sherer TB, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000 Dec; 3 (12): 1301-6
57. Janetzky B, Hauck S, Youdim MB, et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett 1994 Mar 14; 169 (1-2): 126-8
58. Muftuoglu M, Elibol B, Dalmizrak O, et al. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord 2004 May; 19 (5): 544-8
59. Schapira AH, Mann VM, Cooper JM, et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990 Dec; 55 (6): 2142-5
60. Gu M, Cooper JM, Taanman JW, et al. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol 1998 Aug; 44 (2): 177-86
61. Trimmer PA, Borland MK, Keeney PM, et al. Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies. J Neurochem 2004 Feb; 88 (4): 800-12
62. Sherer TB, Betarbet R, Stout AK, et al. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 2002 Aug 15; 22 (16): 7006-15
63. Lee HJ, Shin SY, Choi C, et al. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem 2002 Feb 15; 277 (7): 5411-7
64. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998 Apr 9; 392 (6676): 605-8
65. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000 May 25; 342 (21): 1560-7
66. Hedrich K, Eskelson C, Wilmot B, et al. Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord 2004 Oct; 19 (10): 1146-57
67. Giasson BI, Lee VM-Y. Are ubiquitination pathways central to Parkinson's disease? Cell 2003; 114: 1-8
68. Mori H, Kondo T, Yokochi M, et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 1998 Sep; 51 (3): 890-2
69. Hayashi S, Wakabayashi K, Ishikawa A, et al. An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Disord 2000 Sep; 15 (5): 884-8
70. van de Warrenburg BP, Lammens M, Lucking CB, et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 2001 Feb 27; 56 (4): 555-7
71. Farrer M, Chan P, Chen R, et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001 Sep; 50 (3): 293-300
72. Pramstaller PP, Schlossmacher MG, Jacques TS, et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol 2005 Sep; 58 (3): 411-22
73. Zhang Y, Gao J, Chung KK, et al. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci U S A 2000 Nov 21; 97 (24): 13354-9
74. Shimura H, Hattori N, Kubo S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000 Jul; 25 (3): 302-5
75. Ko HS, von Coelln R, Sriram SR, et al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci 2005 Aug 31; 25 (35): 7968-78
76. Giasson BI, Lee VM-Y. Parkin and the molecular pathways of Parkinson's disease. Neuron 2001 Sep 27; 31 (6): 885-8
77. Kim YS, Patel S, Lee SJ. Lack of direct role of parkin in the steady-state level and aggregation of alpha-synuclein and the clearance of pre-formed aggregates. Exp Neurol 2006 Feb; 197 (2): 538-41
78. Miller DW, Crawley A, Gwinn-Hardy K, et al. Unaltered alpha-synuclein blood levels in juvenile Parkinsonism with a parkin exon 4 deletion. Neurosci Lett 2005 Feb 21; 374 (3): 189-91
79. von Coelln R, Thomas B, Andrabi SA, et al. Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy. J Neurosci 2006 Apr 5; 26 (14): 3685-96
80. Darios F, Corti O, Lucking CB, et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet 2003 Mar 1; 12 (5): 517-26
81. Goldberg MS, Fleming SM, Palacino JJ, et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 2003 Oct 31; 278 (44): 43628-35
82. Perez FA, Palmiter RD. Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci U S A 2005 Feb 8; 102 (6): 2174-9
83. von Coelln R, Thomas B, Savitt JM, et al. Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl Acad Sci U S A 2004 Jul 20; 101 (29): 10744-9
84. Palacino JJ, Sagi D, Goldberg MS, et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004 Apr 30; 279 (18): 18614-22
85. Greene JC, Whitworth AJ, Kuo I, et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A 2003 Apr 1; 100 (7): 4078-83
86. Pesah Y, Pham T, Burgess H, et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 2004 May; 131 (9): 2183-94
87. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003 Jan 10; 299 (5604): 256-9
88. Wilson MA, Collins JL, Hod Y, et al. The 1.1-A resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson's disease. Proc Natl Acad Sci U S A 2003 Aug 5; 100 (16): 9256-61
89. Tao X, Tong L. Crystal structure of human DJ-1, a protein associated with early onset Parkinson's disease. J Biol Chem 2003 Aug 15; 278 (33): 31372-9
90. Lee SJ, Kim SJ, Kim IK, et al. Crystal structures of human DJ-1 and Escherichia coli Hsp31, which share an evolutionarily conserved domain. J Biol Chem 2003 Nov 7; 278 (45): 44552-9
91. Honbou K, Suzuki NN, Horiuchi M, et al. Crystallization and preliminary crystallographic analysis of DJ-1, a protein associated with male fertility and parkinsonism. Acta Crystallogr D Biol Crystallogr 2003 Aug; 59 (Pt 8): 1502-3
92. Huai Q, Sun Y, Wang H, et al. Crystal structure of DJ-1/RS and implication on familial Parkinson's disease. FEBS Lett 2003 Aug 14; 549 (1-3): 171-5
93. Bandyopadhyay S, Cookson MR. Evolutionary and functional relationships within the DJ1 superfamily. BMC Evol Biol 2004 Feb 19; 4: 6
94. Zhang L, Shimoji M, Thomas B, et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet 2005 Jul 15; 14 (14): 2063-73
95. Yokota T, Sugawara K, Ito K, et al. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem Biophys Res Commun 2003 Dec 26; 312 (4): 1342-8
96. Martinat C, Shendelman S, Jonason A, et al. Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES-derived cell model of primary Parkinsonism. PLoS Biol 2004 Nov; 2 (11): E327
97. Shendelman S, Jonason A, Martinat C, et al. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol 2004 Nov; 2 (11): E362
98. Hod Y, Pentyala SN, Whyard TC, et al. Identification and characterization of a novel protein that regulates RNA-protein interaction. J Cell Biochem 1999 Mar 1; 72 (3): 435-44
99. Abou-Sleiman PM, Healy DG, Quinn N, et al. The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann Neurol 2003 Sep; 54 (3): 283-6
100. Gorner K, Holtorf E, Odoy S, et al. Differential effects of Parkinson's disease-associated mutations on stability and folding of DJ-1. J Biol Chem 2004 Feb 20; 279 (8): 6943-51
101. Miller DW, Ahmad R, Hague S, et al. L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J Biol Chem 2003 Sep 19; 278 (38): 36588-95
102. Olzmann JA, Brown K, Wilkinson KD, et al. Familial Parkinson's disease-associated L166P mutation disrupts DJ-1 protein folding and function. J Biol Chem 2004 Feb 27; 279 (9): 8506-15
103. Chen L, Cagniard B, Mathews T, et al. Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem 2005 Jun 3; 280 (22): 21418-26
104. Goldberg MS, Pisani A, Haburcak M, et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 2005 Feb 17; 45 (4): 489-96
105. Kim RH, Smith PD, Aleyasin H, et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A 2005 Apr 5; 102 (14): 5215-20
106. Meulener M, Whitworth AJ, Armstrong-Gold CE, et al. Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. Curr Biol 2005 Sep 6; 15 (17): 1572-7
107. Canet-Aviles RM, Wilson MA, Miller DW, et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A 2004 Jun 15; 101 (24): 9103-8
108. Kinumi T, Kimata J, Taira T, et al. Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. Biochem Biophys Res Commun 2004 May 7; 317 (3): 722-8
109. Mitsumoto A, Nakagawa Y, Takeuchi A, et al. Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat. Free Radic Res 2001 Sep; 35 (3): 301-10
110. Valente EM, Salvi S, Ialongo T, et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004 Sep; 56 (3): 336-41
111. Unoki M, Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 2001 Jul 27; 20 (33): 4457-65
112. Hatano Y, Li Y, Sato K, et al. Novel PINK1 mutations in early-onset parkinsonism. Ann Neurol 2004 Sep; 56 (3): 424-7
113. Rohe CF, Montagna P, Breedveld G, et al. Homozygous PINK1 C-terminus mutation causing early-onset parkinsonism. Ann Neurol 2004 Sep; 56 (3): 427-31
114. Ibanez P, Lesage S, Lohmann E, et al. Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain 2006 Mar; 129 (Pt 3): 686-94
115. Silvestri L, Caputo V, Bellacchio E, et al. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 2005 Nov 15; 14 (22): 3477-92
116. Deng H, Jankovic J, Guo Y, et al. Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun 2005 Dec 2; 337 (4): 1133-8
117. Beilina A, van der BM, Ahmad R, et al. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc Natl Acad Sci U S A 2005 Apr 19; 102 (16): 5703-8
118. Park J, Lee SB, Lee S, et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006 Jun 29; 441: 1162-6
119. Clark IE, Dodson MW, Jiang C, et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006 Jun 29; 441: 1157-61
120. Tang B, Xiong H, Sun P, et al. Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Hum Mol Genet 2006 Jun 1; 15 (11): 1816-25
121. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004 Nov 18; 44 (4): 601-7
122. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004 Nov 18; 44 (4): 595-600
123. Taylor JP, Mata IF, Farrer MJ. LRRK2: a common pathway for parkinsonism, pathogenesis and prevention? Trends Mol Med 2006 Feb; 12 (2): 76-82
124. Paisan-Ruiz C, Lang AE, Kawarai T, et al. LRRK2 gene in Parkinson disease. Neurology 2005 Sept 13; 65 (5): 696-700
125. Deng H, Le W, Guo Y, et al. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol 2005 Jun; 57 (6): 933-4
126. Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005 Jan 29; 365 (9457): 415-6
127. Di Fonzo A, Rohe CF, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005 Jan 29; 365 (9457): 412-5
128. Kachergus J, Mata IF, Hulihan M, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005 Apr; 76 (4): 672-80
129. Hernandez D, Paisan RC, Crawley A, et al. The dardarin G2019S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neurosci Lett 2005 Dec 9; 389 (3): 137-9
130. Nichols WC, Pankratz N, Hernandez D, et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 2005 Jan 29; 365 (9457): 410-2
131. Giasson BI, Covy JP, Bonini NM, et al. Biochemical and pathological characterization of Lrrk2. Ann Neurol 2006 Feb; 59 (2): 315-22
132. West AB, Moore DJ, Biskup S, et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 2005 Nov 15; 102 (46): 16842-7
133. Strauss KM, Martins LM, Plun-Favreau H, et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 2005 Aug 1; 14 (15): 2099-111
134. Tieu K, Perier C, Caspersen C, et al. D-beta-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest 2003 Sep; 112 (6): 892-901